Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Obesity 3 Breast Neoplasms 3 Prostatic Neoplasms 2 Overweight 2 Melanoma 2 Substance Withdrawal Syndrome 1 Skin Neoplasms 1 Metabolic Syndrome 1 Kidney Neoplasms 1 Inflammation 1 Glioma 1 Glioblastoma 1 Dyslipidemias 1 Chronic Pain 1 Carcinoma, Lobular 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1

Interventions

Temozolomide 159 Bevacizumab 69 Radiotherapy 68 Magnetic Resonance Spectroscopy 68 Irinotecan 31 Surgical Procedures, Operative 27 Radiation 24 Carboplatin 23 Specimen Handling 20 Carmustine 20 Blood Specimen Collection 20 Nivolumab 19 Aminolevulinic Acid 18 Biopsy 17 Lomustine 16 pembrolizumab 13 Radiotherapy, Intensity-Modulated 13 Cyclophosphamide 13 trametinib 12 fluorodopa F 18 12 X-Rays 12 Radiosurgery 12 Erlotinib Hydrochloride 12 Topotecan 11 Everolimus 11 Magnetic Resonance Imaging 10 IL13-PE38 10 dabrafenib 9 Etoposide 9 Drug Therapy 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Glioma × Naltrexone × Clear all

NCT01303835 2015-07-17

Low Dose Naltrexone for Glioma Patients

Duke University

Phase 2 Completed

110 enrolled 9 charts

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡